Acceleron recieves $1.

Acceleron recieves $1 http://tadora.org .5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy Acceleron Pharma, Inc., a biopharmaceutical firm developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical research of ACE-031 in Duchenne Muscular Dystrophy , a disabling neuromuscular disease where patients encounter a progressive lack of muscle strength and mass. ACE-031 is an investigational protein therapeutic designed to build muscle and increase power by blocking proteins that inhibit muscle mass growth and strength.

The grants are awarded to therapeutic discovery tasks that show an acceptable potential to result in new therapies to take care of regions of unmet medical need or prevent, detect or deal with chronic or severe conditions and diseases, decrease the long-term growth of healthcare costs in the usa, or significantly progress the goal of curing cancer within 30 years.. Acceleron receives grants for five tasks under QTDP program Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and cells including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five tasks beneath the Qualifying Therapeutic Discovery Task program, enacted as part of the Patient Protection and Affordable Care Action of 2010 .